*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Jiaying Liu
BME PhD Thesis Defense Presentation
Date: June 6th, 2019
Time: 11am-1pm
Location: EBB, CHOA room
(Bluejeans call-in available at bottom)
Advisor:
Dr.Krishnendu Roy
Committee:
Dr. M.G.Finn (Chemistry and Biochemistry)
Dr.Robert Guldberg (University of Oregon)
Dr.Ravi Kane
Dr.Susan Thomas
Title: Design and Development of Synthetic Nanoparticle Antibodies to Deplete Selected Target Cells for Cancer Immunotherapy
Abstract:
Monoclonal antibodies (mAbs) have shown great promise as immunotherapy of cancer in the past decades. They mediate the antibody-dependent immune responses to eliminate the malignant or suppressive cells and proteins and restore anti-cancer immunity. However, the application of monoclonal antibodies as therapeutics is greatly hampered by its high production cost as well as high dosage required to generate significant therapeutic effect due to limited tissue penetration. Besides, monoclonal antibodies targeting some important immunological targets, such as myeloid-derived suppressor cells (MDSCs), regulatory T cells, are still awaiting to be developed.
Here, we have developed a novel type of artificial antibodies, the synthetic nanoparticle antibodies (SNAbs), which are Janus nanoparticles multivalently displaying both binding ligands for the selected cellular targets and Fc-mimicking ligands that can activate Fc receptors. Our primary hypothesis is that the designed SNAbs could induce ADCC/ADCP of cellular targets efficiently both in vitro and in vivo. A simple chemistry method to fabricate Janus gold nanoparticles and to modify these nanoparticles with peptide ligands was designed to make SNAbs. Myeloid derived suppressor cells are selected as our primary cell of interest. We evaluated the capability of SNAbs to target MDSCs in both ex vivo assays and in vivo tumor model systems. We showed that SNAbs can selectively induce antibody-dependent killing of MDSCs in the mixture of various types of immune cells and are also able to deplete MDSCs in a tumor model. The research completed in this thesis demonstrated that the SNAbs are a functional alternative to monoclonal antibodies and hold great promise as a potent immunotherapy for cancer.
To join the Meeting by bluejeans:
https://bluejeans.com/873858183
